Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

They called it the “VIVA ZYPREXA” campaign to off label market Eli Lilly Zyprexa as a fix for unapproved usage. Zyprexa (Olanzapine) is known as an atypical antipsychotic It’s ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...